Repetitive analyses of P-glycoprotein in chronic myeloid leukaemia

Acta Clinica Belgica

Volumn 55, Issue 4, 2000, Pages 215-221

  De Moerloose, B ^a   Muylaert, A ^a   Gemmel, F ^a   Janssens, A ^a   Poppe, B ^a   Dhooge, C ^a   Benoit, Y ^a   Van Hove, W ^a   Philippe, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic myeloid leukaemia; Flow cytometry; MDR; P glycoprotein

Indexed keywords

ALPHA2 INTERFERON; ASPARAGINASE; CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; HYDROXYUREA; IDARUBICIN; METHOTREXATE; RHODAMINE 123; VALSPODAR; VINCRISTINE;

ADULT; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MALE; MULTIDRUG RESISTANCE; PATIENT MONITORING; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 0033752813     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.2000.11754299     Document Type: Article

References (27)

1. Molecular mechanisms of drug resistance in tumours
2. Multidrug resistance and the role of P-glycoprotein knockout mice
3. Biochemistry of multidrug resistance mediated by the multidrug transporter
4. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
5. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
6. P-glycoprotein in adult hematologic malignancies
7. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
8. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis
9. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia
10. Expression of the multidrug resistance gene in myeloid leukemias
11. Multidrug resistance (mdr 1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
12. Over-expression of MDR-related p170 glycoprotein in chronic myeloid leukemia
13. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia
14. Studies of P-glycoprotein in chronic myelogenous leukaemia patients: Expression, activity and correlations with CD34 antigen
15. Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia
16. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - First experience with their reversal
17. Interaction of cyclosporin A and etoposide. Clinical and in vitro assessment in blast phase of chronic myeloid leukaemia
18. Reversal of MDR in acute leukemia and Non-Hodgkin's lymphoma
19. Resistance to chemotherapy in acute leukemia
20. Belgian consensus recommendations for flow cytometric immunopheno-typing
21. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein
22. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia
23. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
24. Methods to detect P-glycoprotein-associated Multidrug Resistance in patients' tumors: Consensus recommendations
25. The detection of rhodamine 123 efflux at low levels of drug resistance
26. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia
27. Clinical significance of P-glycoprotein in multidrug resistance malignancies